Laura A. Coruzzi Ph.D.
Partner

Contact

(T) +1.212.326.8383
(F) +1.212.755.7306

Education

  • Fordham University (J.D. 1985; Ph.D. in Biology 1979, specializing in cell biology, with a postdoctoral fellowship at Mt. Sinai School of Medicine, New York; M.S. in Biology with honors 1975; B.S. in Biology with honors 1973)

Bar Admissions

  • New York, U.S. District Courts for the Southern and Eastern Districts of New York, U.S. Court of Appeals for the Federal Circuit, and registered to practice before the U.S. Patent & Trademark Office

Dr. Laura Coruzzi has represented clients in biotechnology and pharmaceuticals for close to 30 years. Prior to joining Jones Day, she practiced at Pennie & Edmonds LLP and was one of the first members of that firm's biotechnology group founded by S. Leslie Misrock, affectionately known as the "father of biotechnology patent law." Laura's practice has evolved with the patent laws and matured with the needs of the biotechnology and pharmaceutical industries. Her practice involves all aspects of patent law as it relates to a variety of disciplines in the life sciences, including genetic engineering, molecular biology, virology, vaccines, immunology, therapeutic antibodies, biologic and small molecule therapeutics, diagnostics, drug discovery, and drug delivery.

Laura's patent procurement practice focuses on strategic planning and management of patent portfolios designed to protect emerging new technologies as well as mature biologic and pharmaceutical therapeutics and diagnostics. She counsels clients on portfolio evaluation, due diligence investigations, patent prosecution and interferences, European oppositions, and licensing. Laura's practice also encompasses patent litigation and appeals before the USPTO Board of Appeals and the Federal Circuit. She is a member of the Jones Day team representing Myriad in Association for Molecular Pathology v. Myriad Genetics (2011) upholding the patent-eligibility of isolated human genes. Prior to joining Jones Day, she and her team won reversal of an $18 million jury verdict in 2000 for Cadus Pharmaceutical Corporation in a case involving cell-based assays for drug screening.

Laura is frequently invited to speak at symposia on patent law issues related to life sciences.


Laura Coruzzi